News & Updates

A significant increase in blood pressure (BP) appears predictive of therapeutic response to vascular endothelial growth factor (VEGF) inhibitors but does not limit treatment duration even in patients with severe elevations, suggests a study.

Patients treated with teprotumumab for thyroid eye disease frequently develop otologic symptoms, and those who already have hearing problems prior to treatment are at heightened risk of progressing to sensorineural hearing loss, a study reports.

Localized administration of colistin reduces the incidence of systemic adverse events in patients with lower respiratory tract infection (LRTI), a recent study has shown.

Real-world interim findings from the phase IV, noninterventional EMPOWER trial showed reduced attack rates and improved quality of life (QoL) in individuals who received lanadelumab for the treatment of hereditary angioedema (HAE).

Adding darolutamide to androgen-deprivation therapy (ADT) plus docetaxel significantly increases overall survival (OS) in patients with metastatic, hormone-sensitive prostate cancer (mHSPC), according to the ARASENS* trial presented at the ASCO GUCS 2022.